Celltrion's inhalable Regkirona gets nod for Phase 1 trials in Australia

Home > Business > Industry

print dictionary print

Celltrion's inhalable Regkirona gets nod for Phase 1 trials in Australia

 
Celltrion’s inhalable form of Regkirona, a Covid-19 treatment, won approval for Phase 1 clinical trials in Australia, the company said Tuesday.
 
Since July last year, Celltrion has been working with Durham, North Carolina-based Inhalon Biopharma to develop an inhalable form of Regkirona, which allows for the conveying of the treatment directly into the airways using an inhaler. It will make delivery more convenient, according to Celltrion.
 
The two companies have injected the inhalable form of Covid-19 treatment into rats in January and were able to observe meaningful results about safety and tolerability.
 
Upon authorization from Australia's Therapeutic Goods Administration, the Phase 1 clinical trial will be conducted on 24 healthy people. The Phase 2 clinical trial will start within the year to test the efficacy of the treatment, according to Celltrion.
 
The companies aim to market the inhalable form of treatment for use not only in Covid-19 patients with mild and severe symptoms but also asymptomatic patients and those who had close contact with those infected.  
 
Celltrion said the inhalable form of Regkirona will be able to achieve synergy effects with its rapid antibody diagnostic test kit for the Covid-19, named DiaTrust.
 
“While the pandemic lingers with the spread of virus variants, Celltrion is accelerating the development of the inhalable form of Regkirona in order to offer new options for Covid-19 treatment by strengthening treatment access for medical professionals and patients,” said a spokesperson for Celltrion. “Celltrion will try harder to seek for more measures to prevent the further spread of the virus and end the pandemic.”

BY SARAH CHEA [chea.sarah@joongang.co.kr]
Log in to Twitter or Facebook account to connect
with the Korea JoongAng Daily
help-image Social comment?
s
lock icon

To write comments, please log in to one of the accounts.

Standards Board Policy (0/250자)

What’s Popular Now